Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
High-Resolution Magnetic Resonance Imaging (MRI) Scans to Look for Spread of Melanoma to Nearby Lymph Nodes
This study is currently recruiting participants.
Verified by Redwood Regional Medical Group, December 2008
Sponsored by: Redwood Regional Medical Group
Information provided by: Redwood Regional Medical Group
ClinicalTrials.gov Identifier: NCT00463892
  Purpose

The study is designed to see if a high-resolution MRI scan of lymph node areas near where a melanoma has been removed from the skin can pick up the spread of melanoma to those lymph nodes with a high degree of accuracy.


Condition Intervention Phase
Melanoma
Procedure: High-resolution contrast-enhanced MRI scan
Phase II

MedlinePlus related topics: MRI Scans Melanoma Nuclear Scans
U.S. FDA Resources
Study Type: Interventional
Study Design: Diagnostic, Non-Randomized, Open Label, Uncontrolled, Parallel Assignment, Efficacy Study
Official Title: A Phase II Study of High-Resolution Contrast-Enhanced MRI of Regional Lymph Nodes in Patients With Clinically Localized Invasive Melanoma

Further study details as provided by Redwood Regional Medical Group:

Primary Outcome Measures:
  • Assessment of the sensitivity and specificity of high-resolution MRI scans of regional lymph nodes compared to results from regional lymph node biopsy. [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • Assessment of the sensitivity and specificity of high-resolution MRI scans of regional lymph nodes compared to results from regional lymph node biopsy. [ Time Frame: 5 years ]

Estimated Enrollment: 200
Study Start Date: June 2007
Estimated Study Completion Date: June 2013
Estimated Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Intervention Details:
    Procedure: High-resolution contrast-enhanced MRI scan
    High-resolution contrast-enhanced MRI scan of regional lymph nodes every 6 months on study
Detailed Description:

When a melanoma of the skin is diagnosed, there is some chance it can spread to nearby lymph nodes, and from there to other parts of the body. Currently, patients with melanoma at low risk for spreading to lymph nodes do not get the lymph nodes assessed except by a physical exam. Those at high risk for spreading to lymph nodes get one or more lymph nodes removed surgically to check for melanoma spread. But physical exam alone will often miss small areas of melanoma in lymph nodes; removal of lymph nodes by surgery is painful and can cause complications. Neither assessment tool is optimal.

This study is designed to see if use of very high-resolution contrast-enhanced MRI scans of lymph node areas near the primary melanoma site in the skin can accurately detect small areas of melanoma spread to those lymph nodes. If this turns out to be the case, in the future, MRI scans could potentially be an alternative for assessing lymph nodes, compared to physical exams alone or surgical removal of the lymph nodes.

In this study, patients with low risk melanoma will receive very high-resolution MRI scans of nearby lymph nodes every 6 months for 5 years of follow-up. If the MRI looks abnormal, the lymph nodes will be biopsied, and results from the biopsy compared to the results from the MRI.

Patients with high risk melanoma will get a baseline MRI of the nearby lymph nodes, and then one or more lymph nodes will be removed (usually by sentinel lymph node biopsy) regardless of the MRI results. Again, results from the biopsy will be compared to the results from the MRI. MRI's will still be repeated every 6 months to assess whether lymph nodes not removed at surgery develop any changes.

We plan to enroll 200 patients on this study and by the end of the study will have a measure of the sensitivity and specificity of high-resolution MRI scans in the detection of melanoma involvement of regional lymph nodes.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • history of invasive cutaneous melanoma stages 1-3 within 2 years of treatment of the melanoma by primary excision
  • eligible whether or not a sentinel lymph node biopsy or regional lymph node dissection has been performed
  • adequate renal function (creatinine 2 or less)
  • life expectancy 2 years of more

Exclusion Criteria:

  • history of severe claustrophobia precluding MRI scans
  • known hypersensitivity or other contraindication to gadolinium contrast
  • known presence of metastatic melanoma at sites beyond regional lymph nodes (stage 4)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00463892

Contacts
Contact: Jacki Malin, RN (707) 521-3802 jmalin@rrmginc.com
Contact: Ann Lowry, RN (707) 521-3814 alowry@rrmginc.com

Locations
United States, California
Redwood Regional Medical Group Recruiting
Sebastopol, California, United States, 95472
Contact: Jacki Malin, RN     707-521-3802     jmalin@rrmginc.com    
Contact: Ann Lowry     (707) 521-3814     alowry@rrmginc.com    
Principal Investigator: Peter Brett, M.D.            
Sponsors and Collaborators
Redwood Regional Medical Group
Investigators
Principal Investigator: Peter Brett, M.D. Redwood Regional Medical Group
Principal Investigator: David Feinberg, M.D., Ph.D. Redwood Regional Medical Group
  More Information

Click here for more information on clinical trials at RRMG  This link exits the ClinicalTrials.gov site

Responsible Party: Redwood Regional Medical Group ( Peter Brett, M.D. )
Study ID Numbers: RRMG #07-001
Study First Received: April 19, 2007
Last Updated: December 19, 2008
ClinicalTrials.gov Identifier: NCT00463892  
Health Authority: United States: Institutional Review Board

Keywords provided by Redwood Regional Medical Group:
melanoma
lymph nodes
magnetic resonance imaging
screening
detection

Study placed in the following topic categories:
Neuroectodermal Tumors
Nevus, Pigmented
Neoplasms, Germ Cell and Embryonal
Neuroepithelioma
Nevus
Neuroendocrine Tumors
Melanoma

Additional relevant MeSH terms:
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas

ClinicalTrials.gov processed this record on January 16, 2009